{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-046225","form_type":"8-K","ticker":"CALC","cik":"0001534133","company_name":"CalciMedica, Inc.","filed_at":"2025-03-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.922683+00:00","generated_at":"2026-05-25T10:14:43.458005+00:00","sec_items":["1.01","2.03","3.02","8.01","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"CalciMedica secures up to $32.5M credit facility; $10M funded at close extends cash runway into mid-2026","bullets":["Loan agreement with Avenue Venture Opportunities Fund II provides up to $32.5M; initial tranche $10M funded Feb 28, 2025.","Additional tranches of $7.5M and $15M available upon achieving clinical milestones and mutual agreement.","Interest rate: prime + 5% (floor 12.75%); interest-only for 18 months; maturity Sept 1, 2028.","Warrant issued for 641,163 shares at $2.32 per share; exercisable until Feb 28, 2030.","No financial covenants; no minimum cash requirement; up to $2M principal convertible at 120% of stock purchase price."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-046225","json":"https://secwatch.observer/filing/0001193125-25-046225.json","markdown":"https://secwatch.observer/filing/0001193125-25-046225.md","text":"https://secwatch.observer/filing/0001193125-25-046225.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534133/000119312525046225/0001193125-25-046225-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534133/000119312525046225/d940326d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T10:14:43.458005+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b966acaeacb1b25443b2c81aae5e4cdcb79b29d8","claim":"CalciMedica, Inc. incurred credit facility of up to $32,500,000 with Avenue Venture Opportunities Fund II, L.P. at annual rate equal to the greater of (a) the sum of 5.00% plus the prime rate as maturing September 1, 2028.","evidence_excerpt":"On February 28, 2025 (the “Closing Date”), CalciMedica, Inc. (the “Company”) entered into a Loan and Security Agreement and the Supplement to the Loan and Security Agreement (together, the “Loan Agreement”) with Avenue Venture Opportunities Fund II, L.P. (the “Lender”) and Avenue Capital Management II, L.P., as administrative agent and collateral agent, for growth capital loans in an aggregate principal amount of up to $32,500,000 (the “Loan”), with (i) $10,000,000 funded on the Closing Date (“Tranche 1”), (ii) up to $7,500,000 to be made available to the Company between September 1, 2025 and March 31, 2026, subject to, among other things, the Company’s achievement of certain milestones with respect to certain of its ongoing clinical trials (“Tranche 2”) and (iii) up to $15,000,000 to be made available to the Company between October 1, 2025 and March 31, 2026, subject to, among other things, (a) the Company’s achievement of additional milestones with respect to certain of its ongoing c","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312525046225/0001193125-25-046225-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"credit facility"},{"label":"Principal","value":"up to $32,500,000"},{"label":"Counterparty","value":"Avenue Venture Opportunities Fund II, L.P."},{"label":"Rate","value":"annual rate equal to the greater of (a) the sum of 5.00% plus the prime rate as"},{"label":"Maturity","value":"September 1, 2028"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}